Harrow (HROW) Projected to Post Earnings on Monday

Harrow (NASDAQ:HROW) will likely be announcing its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect the company to post earnings of $0.17 per share and revenue of $98.47 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 8:00 AM ET.

Harrow (NASDAQ:HROW) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.28). Harrow had a negative net margin of 13.51% and a negative return on equity of 38.00%. The firm had revenue of $70.66 million for the quarter, compared to analyst estimates of $70.35 million.

Harrow Stock Performance

Shares of NASDAQ HROW opened at $28.04 on Monday. The company has a debt-to-equity ratio of 19.70, a current ratio of 2.24 and a quick ratio of 2.08. Harrow has a one year low of $26.96 and a one year high of $54.85. The business’s 50-day moving average price is $32.86 and its two-hundred day moving average price is $38.42. The company has a market capitalization of $1.05 billion, a P/E ratio of -28.04 and a beta of 0.18.

Analysts Set New Price Targets

A number of research analysts recently weighed in on HROW shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Harrow in a research note on Friday, October 16th. BTIG Research restated a “buy” rating and issued a $63.00 price objective on shares of Harrow in a research note on Wednesday, October 7th. Wall Street Zen upgraded Harrow from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Zacks Research upgraded shares of Harrow from a “strong sell” rating to a “hold” rating in a research report on Wednesday, September 9th. Finally, Leerink Partners initiated coverage on shares of Harrow in a report on Wednesday, September 9th. They set an “outperform” rating and a $45.00 price objective on the stock. Seven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Harrow presently has an average rating of “Moderate Buy” and an average price target of $66.17.

Insider Buying and Selling

In other news, insider Amir Shojaei sold 11,250 shares of the firm’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $40.00, for a total value of $450,000.00. Following the completion of the transaction, the insider owned 11,250 shares in the company, valued at $450,000. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 12.80% of the company’s stock.

About Harrow

Harrow, Inc is an ophthalmic pharmaceutical company focused on developing, acquiring, and commercializing prescription therapies for eye care. The company’s portfolio addresses conditions and procedures involving the ocular surface, anterior segment, and retina, with products intended for use by ophthalmologists and other eye-care professionals.

Harrow’s commercial products include VEVYE, a cyclosporine ophthalmic solution for the treatment of dry eye disease, and IHEEZO, a chloroprocaine hydrochloride ophthalmic gel used for ocular surface anesthesia during ophthalmic procedures.